Filament Health has shipped its patented psilocybin drug candidate PEX010 to Austin Health in Melbourne for the PSI-PHY trial, the first study to combine psilocybin-assisted physiotherapy for refractory motor functional neurological disorder (FND). Sponsored by The University of Melbourne and funded by the Australian Government, this trial explores psilocybin's potential to enhance physiotherapy by modifying brain signaling to improve motor function. This marks the first use of PEX010 in a movement disorder and highlights Filament's role as a leading supplier of pharmaceutical-grade natural psilocybin. The study could open new treatment avenues for FND, a condition with no approved drug therapies.
Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...
A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...
Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...
